Alaunos Therapeutics, Inc.(TCRT)— Stock Profile, AI Score & Financials
Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated .
Alaunos Therapeutics, Inc. (TCRT) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores TCRT at 5.5/100 on a 32-signal composite quality model, placing it at rank #2,953 of 2,962 stocks — the bottom half of the AI-ranked universe. Top institutional holders of TCRT by reported 13-F value include BlackRock, GEODE CAPITAL MANAGEMENT, VANGUARD FIDUCIARY, based on the most recent SEC filings. TCRT trades on the Nasdaq exchange and files with the SEC under CIK 1107421. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate TCRT daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Alaunos Therapeutics, Inc. directly from SEC EDGAR.
AI Quality Score
5.5/100
AI Rank
#2,953
Revenue
$0.00
Net Income
$-952.0K
TCRT key financials by period
Alaunos Therapeutics, Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
Period
Form
Revenue
Net income
Operating margin
FY 2025
10-K
$5.0K
$-4.2M
—
FY 2024
10-K
$10.0K
$-4.7M
—
FY 2023
10-K
$5.0K
$-4.7M
—
FY 2022
10-K
$2.9M
$-37.7M
—
FY 2021
10-K
$398.0K
$-78.8M
—
FY 2018
10-K
$146.0K
$-53.1M
—
Institutions holding TCRT
Institutional investors reporting a position in Alaunos Therapeutics, Inc. on SEC Form 13F.
